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Introduction {#sec001}
============

Juvenile myelomonocytic leukemia (JMML) is an aggressive myeloid neoplasm of early childhood characterized by the excessive proliferation of myelomonocytic cells and hypersensitivity to granulocyte-macrophage colony-stimulating factor \[[@pone.0145394.ref001]\]. JMML is categorized as an overlap of myelodysplastic syndrome and myeloproliferative neoplasm by the World Health Organization classification \[[@pone.0145394.ref002]\]. Mutations in *PTPN11*, *NF1*, *NRAS*, *KRAS*, or *CBL*, which induce deregulation of the RAS signaling pathway, are responsible for the pathogenesis of up to 80% of cases of JMML \[[@pone.0145394.ref003]--[@pone.0145394.ref005]\]. Recently, we identified secondary somatic mutations in *SETBP1* and *JAK3* in patients with JMML that were associated with poor prognosis \[[@pone.0145394.ref006]--[@pone.0145394.ref008]\]. The clinical management of patients with JMML according to the genetic status is of great interest because of the possible prognostic variety in JMML; however, this idea remains controversial \[[@pone.0145394.ref009]--[@pone.0145394.ref010]\].

Methylation of cytosines in promoter CpG dinucleotides is an important negative regulator of gene expression in the human genome. Aberrant methylation of CpG islands in the promoter regions of tumor-suppressor genes plays a fundamental role in the pathogenesis of various cancers \[[@pone.0145394.ref011],[@pone.0145394.ref012]\], including myeloid malignancies \[[@pone.0145394.ref013],[@pone.0145394.ref014]\]. Several studies have described aberrant DNA methylation in JMML \[[@pone.0145394.ref015],[@pone.0145394.ref016]\], but most researchers studied small cohorts, excluding a report of 127 cases of JMML by the European Working Group of MDS (EWOG-MDS) showing that aberrant DNA methylation of four genes (*BMP4*, *CALCA*, *CDKN2B*, and *RARB)* is associated with poor prognosis \[[@pone.0145394.ref017]\]. However, no report has confirmed this observation because JMML is extremely rare. In this study, to further clarify the clinical importance of aberrant DNA methylation in JMML, we quantitatively evaluated the DNA methylation pattern in the promoter regions of 16 selected genes using pyrosequencing of genomic DNA from bone marrow specimens at diagnosis from 92 patients with JMML.

Materials and Methods {#sec002}
=====================

Patients {#sec003}
--------

We studied 92 children (61 males and 31 females) with JMML or Noonan syndrome-associated myeloproliferative disorder (NS-MPD) who were diagnosed in various institutions throughout Japan. The diagnosis of JMML was based on internationally accepted criteria \[[@pone.0145394.ref002]\]. Written informed consent was obtained from each patient's parents before sample collection. This study was approved by the Ethics Committees of Nagoya University Graduate School of Medicine. The clinical records of patients were obtained from each institution. The detailed patient characteristics were described in our previous report^7^ and are summarized in [Table 1](#pone.0145394.t001){ref-type="table"}. With genetic analysis, mutations in *PTPN11*, *NF1*, *NRAS*, *KRAS*, and *CBL* were found in 39 (42%), 7 (8%), 12 (13%), 13 (14%), and 11 (12%) patients, respectively. In addition, 16 patients had *SETBP1* or *JAK3* mutations \[[@pone.0145394.ref007]\].

10.1371/journal.pone.0145394.t001

###### Patient characteristics.

![](pone.0145394.t001){#pone.0145394.t001g}

                                               Total cohort (n = 92)   AMS 0 (n = 25)    AMS 1--2 (n = 54)   AMS 3--4 (n = 13)
  -------------------------------------------- ----------------------- ----------------- ------------------- -------------------
  Gender (Male/Female)                         61/31                   13/12             39/15               9/4
  Median age at diagnosis, months (range)      16 (1--160)             8 (1--59)         23 (1--160)         29 (1--74)
  Diagnosis (JMML/NS-MPD)                      85/7                    20/5              52/2                13/0
  Hypermethylated genes, n                                                                                   
  *BMP4*                                       41                      0                 29                  12
  *CALCA*                                      32                      0                 20                  12
  *CDKN2A*                                     32                      0                 20                  12
  *RARB*                                       13                      0                 9                   4
  Genetic mutations in the RAS pathway, n                                                                    
  *PTPN11*                                     39                      6                 26                  7
  *NF1*                                        9                       1                 5                   3
  *RAS (NRAS/KRAS)*                            28 (15/13)              8 (5/3)           18 (9/9)            2 (1/1)
  *CBL*                                        14                      7                 3                   3
  No mutation                                  10                      4                 5                   1
  Secondary genetic mutations, n                                                                             
  *SETBP1* and *JAK3*                          1                       0                 1                   0
  *SETBP1* only                                6                       0                 5                   1
  *JAK3* only                                  9                       0                 5                   4
  No secondary mutation                        76                      25                43                  8
  Metaphase cytogenetics at diagnosis, n                                                                     
  Normal karyotype                             76                      24                41                  11
  Monosomy 7                                   8                       1                 7                   0
  Trisomy 8                                    4                       0                 3                   1
  Other abnormalities                          4                       0                 3                   1
  WBC at diagnosis, ×10^9^/L, median (range)   30.0 (1.0--563)         26.9 (1.0--131)   29.7 (5.6--113)     43.1 (15.3--563)
  Mon at diagnosis, ×10^9^/L, median (range)   4.6 (0.2--31.6)         4.5 (0.2--18.4)   4.5 (0.5--20.8)     5.8 (1.1--31.6)
  HbF at diagnosis, %, median (range)          21 (0--68)              8 (0--68)         22 (0--63)          24 (8--56)
  PLT at diagnosis, ×10^9^/L, median (range)   61.0 (1.4--483)         112 (5.0--373)    53.0 (1.4--483)     49.0 (8--132)
  HSCT (Yes/No)                                56/36                   6/19              43/11               7/6
  Probability of 5-year TFS, % (95% CI)        15 (6--27)              69 (45--84)       6 (1--17)           0
  Survival outcome (Alive/Dead)                62/30                   20/5              41/13               1/12
  Probability of 5-year OS, % (95% CI)         60 (46--71)             76 (45--91)       68 (50--81)         8 (0--29)

Abbreviations: AMS, aberrant methylation score; CI, confidential interval; HbF, hemoglobin F; HSCT, hematopoietic stem cell transplantation; JMML, juvenile myelomonocytic leukemia; Mon, monocytes; NS-MPD, Noonan syndrome-associated myeloproliferative disorder; OS, overall survival; PLT, platelet count; TFS, transplantation-free survival; WBC, white blood cell count.

Laboratory methods {#sec004}
------------------

We examined genomic DNA derived from bone marrow specimens at the diagnosis of JMML or NS-MPD. As normal controls, age- and tissue-matched samples were obtained from 16 healthy donors. Genomic DNA was extracted from the peripheral blood of normal controls and bone marrow specimens of children with JMML using a QIAamp DNA Blood Mini kit (QIAGEN, Hilden, Germany) and a QIAamp DNA Investigator kit (QIAGEN), according to the manufacturer's instructions. The DNA was bisulfite-modified using an EpiTect Bisulfite kit (QIAGEN). We quantified CpG methylation in the promoter regions of 16 candidate genes (*APC*, *BMP4*, *CALCA*, *CDH13*, *CDKN2A*, *CDKN2B*, *CHFR*, *DAPK1*, *ESR1*, *H19*, *IGF2AS*, *MGMT*, *MLH1*, *RARB*, *RASSF1*, and *TP73*), which were reported to be highly methylated in JMML \[[@pone.0145394.ref015]--[@pone.0145394.ref017]\], or other hematological malignancies \[[@pone.0145394.ref018]--[@pone.0145394.ref025]\]. Bisulfite-converted DNA was amplified using a PyroMark PCR kit (QIAGEN) with specific primers for the CpG islands of target genes \[[@pone.0145394.ref026]\]. The informations of the region of each target genes investigated were listed in [S1 File](#pone.0145394.s002){ref-type="supplementary-material"}. To calculate the DNA methylation level of each targeted CpG, the peak heights in the resulting pyrogram describe the ratio of cytosine to thymine at each analyzed CpG site, which reflects the proportion of methylated DNA, and the average methylation of the all CpG sites for each gene was calculated \[[@pone.0145394.ref027]\]. We defined aberrant hypermethylation as higher than three standard deviations above the mean of the methylation level in normal controls.

Statistical analyses {#sec005}
--------------------

Comparisons of proportions were performed using the χ^2^ test for heterogeneity or Fisher's exact test as appropriate. Mean ranks were compared with the Wilcoxon two-sample test. All candidate predictive factors were investigated for their impact on the duration of transplantation-free survival (TFS), which was defined as the interval from diagnosis to hematopoietic stem cell transplantation (HSCT) or death of any cause, and overall survival (OS), which was defined as the time from diagnosis to death regardless of disease status using the Kaplan--Meier estimate. The observation time of patients who had not progressed and who were alive at the last follow-up visit was considered to be censored. Covariates with a *p*-value \<0.10 in univariate analyses were included in multivariate analyses. As estimates of the prognostic effect, hazard ratios (HR) with 95% confidential intervals (CI) were calculated with Cox proportional hazard models. All reported *p*-values were two-sided and the significance level was set at 0.05. Statistical analyses were performed using Stata 12.0 (Stata Corporation, College Station, TX, USA).

Results {#sec006}
=======

Among 16 candidate genes, aberrant hypermethylation of *BMP4* (41/92, 45%), *CALCA* (32/92, 35%), *CDKN2A* (32/92, 35%), *CDKN2B* (4/92, 4%), *H19* (5/92, 5%), and *RARB* (13/92, 14%) was detected in our cohort ([Fig 1A](#pone.0145394.g001){ref-type="fig"}). For the other 10 genes, no hypermethylation exceeding the limit of detection was observed. Hypermethylation of *BMP4*, *CALCA*, *CDKN2A*, and *RARB* in particular, resulted in a poorer outcome as indicated by the Kaplan--Meier estimates for TFS, for which the probabilities of TFS for patients with and without methylation were: 31% and 0% (*p* \<0.001), for *BMP4*; 25% and 4% (*p* = 0.07), for *CALCA*; 25% and 0% (*p* \<0.001), for *CDKN2A*; and 22% and 0% (*p* = 0.04), for *RARB*, respectively ([Fig 1B](#pone.0145394.g001){ref-type="fig"}).

![Summary of DNA methylation in candidate genes.\
(A) The dot plot represents the frequencies of methylated CpG sites for each candidate gene in the 92 patients with juvenile myelomonocytic leukemia. Aberrant hypermethylation was defined as \>3 standard deviations above the mean methylation level of the healthy control population. The threshold values of each gene are shown as red broken lines. (B) Kaplan--Meier plots of the patient groups, defined by aberrant methylation of the indicated genes, are shown for *BMP4*, *CALCA*, *CDKN2A*, *CDKN2B*, *H19*, and *RARB*.](pone.0145394.g001){#pone.0145394.g001}

Thus, we considered that four of the candidate genes were aberrantly hypermethylated (*BMP4*, *CALCA*, *CDKN2B*, and *RARB*) and assigned an aberrant methylation score (AMS; one point for each methylated gene for these four genes) to further assess the genetic and clinical impact of the hypermethylation. Accordingly, 25 (27%), 30 (33%), 24 (26%), 12 (13%), and one (1%) patient had AMSs of 0, 1, 2, 3, and 4, respectively. Among the 7 patients with NS-MPD, three and four had AMSs of 0 and 1, respectively, however, none of the patients had AMS of 2 or more. The AMSs in the cohort of 92 patients with JMML are summarized in [Fig 2A](#pone.0145394.g002){ref-type="fig"}. Of the 16 patients with mutations in *SETBP1* and/or *JAK3*, 0 (0%), 7 (44%), 4 (25%), 4 (25%), and one (6%) patient had AMSs of 0, 1, 2, 3, and 4, respectively. However, of the other 76 patients without mutations in *SETBP1* or *JAK3*, 25 (33%), 23 (30%), 20 (26%), 8 (11%), and 0 (0%) patients had AMSs of 0, 1, 2, 3, and 4, respectively. As shown in [Fig 2B](#pone.0145394.g002){ref-type="fig"}, the AMS of patients with *SETBP1* and/or *JAK3* mutations was significantly higher than that in patients without these secondary mutations (*p* = 0.03).

![Profile of genetic mutations and aberrant methylation.\
(A) Mutation status of RAS pathway genes and secondary genes (*SETBP1* and *JAK3*) identified as gene targets. Aberrant methylation scores (AMS) in a cohort of 92 patients with juvenile myelomonocytic leukemia are summarized. A rhombus denotes a patient with Noonan syndrome-associated myeloproliferative disorder. (B) Mutations in *SETBP1* and *JAK3* were associated with a higher AMS. The mean AMS of patients with *SETBP1* and/or *JAK3* mutations was higher than that of patients without secondary mutations (p = 0.03).](pone.0145394.g002){#pone.0145394.g002}

The patients were classified into three cohorts according to the AMS score ([Table 1](#pone.0145394.t001){ref-type="table"} and [Fig 3](#pone.0145394.g003){ref-type="fig"}). The AMS 0 cohort displayed better survival without HSCT; specifically, the probabilities of 5-year TFS and OS in this cohort were 69% (95% CI, 45%--84%) and 76% (95% CI, 45%--91%), respectively. Patients in the AMS 1--2 cohort were rescued by HSCT. The probabilities of 5-year TFS and OS in this cohort were 6% (95% CI, 1%--17%) and 68% (95% CI, 50%--81%), respectively. In sharp contrast, the prognosis of patients in the AMS 3--4 cohort was not improved by HSCT, as the probabilities of 5-year TFS and OS in this cohort were 0% and 8% (95% CI, 0%--29%), respectively. Indeed, six of seven patients who received allogeneic HSCT in the AMS 3--4 cohort died during observation. Their causes of death consisted of progressive disease (n = 3), veno-occlusive disease (n = 2), and respiratory distress (n = 1), as shown in [Table 2](#pone.0145394.t002){ref-type="table"}.

![Hypermethylation status and clinical outcome in patients with juvenile myelomonocytic leukemia (JMML).\
(A) Kaplan--Meier curves represent the probability of transplantation-free survival (TFS) in the 92 patients with JMML. TFS was defined as the probability of being alive and transplantation free. Both death and transplantation were considered events. The probability of 5-year TFS in the aberrant methylation score (AMS) 0 cohort (solid line) was significantly higher than that in the AMS 1--2 (long dashed line) and AMS 3--4 cohorts (dashed line), p \< 0.001. (B) Kaplan--Meier curves represent the probability of overall survival (OS) in the 92 patients with JMML. Death was considered an event. The probability of OS in both the AMS 0 (solid line) and 1--2 cohorts (long dashed line) was significantly higher than that in the AMS 3--4 cohort (dashed line), p \< 0.001.](pone.0145394.g003){#pone.0145394.g003}

10.1371/journal.pone.0145394.t002

###### Patient characteristics of the AMS 3--4 cohort.

![](pone.0145394.t002){#pone.0145394.t002g}

  UPN   Age (months) / Gender   AMS   Mutation in RAS pathway genes   Mutation in *JAK3* or *SETBP1*   Metaphase cytogenetics   First HSCT   Second HSCT   Observation period from diagnosis (months)   Outcome   Cause of death
  ----- ----------------------- ----- ------------------------------- -------------------------------- ------------------------ ------------ ------------- -------------------------------------------- --------- ----------------------
  2     67 / M                  3     *PTPN11*                        −                                46,XY                    −            −             4                                            Dead      Disease progression
  4     3 / F                   3     *CBL*                           −                                46,XX                    MSD BMT      −             57                                           Alive     \-
  6     74 / F                  3     *NF1*                           \-                               46,XX                    −            −             10                                           Dead      Disease progression
  7     52 / M                  3     *PTPN11*                        \-                               46,XY                    −            −             17                                           Dead      Disease progression
  17    41 / M                  3     *PTPN11*                        *SETBP1*                         47,XY,+8                 UR CBT       −             6                                            Dead      Disease progression
  19    1 / F                   3     \-                              \-                               46,XX                    −            −             4                                            Dead      Disease progression
  21    29 / M                  3     *PTPN11*                        *JAK3*                           45,XY, del(6)(q?),-20    UR CBT       −             4                                            Dead      VOD
  41    3 / M                   3     *PTPN11*                        \-                               46,XY                    −            −             1                                            Dead      Respiratory distress
  43    11 / F                  3     *CBL*                           \-                               46,XX                    −            −             0                                            Dead      Pulmonary bleeding
  45    43 / M                  4     *PTPN11*                        *JAK3*                           46,XY                    UR BMT       UR CBT        6                                            Dead      VOD
  48    23 / M                  3     *NF1*                           *JAK3*                           46,XY                    MMRD BMT     −             5                                            Dead      Disease progression
  49    65 / M                  3     *PTPN11*                        *JAK3*                           46,XY                    UR CBT       UR BMT        14                                           Dead      Disease progression
  53    9 / M                   3     *KRAS*                          \-                               46,XY                    UR BMT       −             7                                            Dead      Respiratory distress

Abbreviations: AMS, aberrant methylation score; BMT, bone marrow transplantation; CBT, cord blood transplantation; F, female; HSCT, hematopoietic stem cell transplantation; M, male; MMRD, mismatched related donor; MSD, matched sibling donor; UR, unrelated; VOD, veno-occlusive disease.

According to multivariate analysis using the Cox proportional hazard model for covariates including AMS ([Table 3](#pone.0145394.t003){ref-type="table"}), an AMS of 1--4 (HR, 4.1; 95% CI, 1.5--11; *p* = 0.006), mutations in *PTPN11* or *NF1* (HR, 3.5; 95% CI, 1.6--7.5; *p* = 0.002), and chromosomal aberrations (HR, 2.3; 95% CI, 1.1--4.7; *p* = 0.021) were independent predictors of poor TFS. Moreover, an AMS of 3--4 (HR, 4.4; 95% CI, 1.7--11; *p* = 0.002), chromosomal aberrations (HR, 4.1; 95% CI, 1.6--11; *p* = 0.004), and platelet counts of less than 33 × 10^9^/L (HR, 3.1; 95% CI, 1.4--7.3; *p* = 0.007) were independent predictors of poor OS. On the contrary, in multivariate analysis for covariates excluding AMS ([Table 3](#pone.0145394.t003){ref-type="table"}), mutations in *PTPN11* or *NF1* (HR, 2.1; 95% CI, 1.2--5.1; *p* = 0.01), chromosomal aberrations (HR, 3.7; 95% CI, 1.9--7.1; *p* \<0.001), and platelet counts of less than 33 x 10^9^/L (HR, 2.0; 95% CI, 1.1--3.5; *p* = 0.02) were independent predictors of poor TFS. Furthermore, chromosomal aberrations (HR, 3.8; 95% CI, 1.5--9.8; *p* = 0.006) and platelet counts of less than 33 × 10^9^/L (HR, 2.8; 95% CI, 1.2--6.2; *p* = 0.015) were independent predictors of poor OS. Comparing these analyses, the AMS refined the predictability of outcomes ([S1 Fig](#pone.0145394.s001){ref-type="supplementary-material"}).

10.1371/journal.pone.0145394.t003

###### Multivariate model for transplantation-free and overall survival.

![](pone.0145394.t003){#pone.0145394.t003g}

  Covariates                      Model without aberrant methylation score   Model with aberrant methylation score                                                                      
  ------------------------------- ------------------------------------------ --------------------------------------- ---------------- ------- ---------------- ------- ---------------- -------
  Mutation in *PTPN11* or *NF1*   2.5 (1.2--5.1)                             0.01                                    2.1 (0.6--7.1)   0.24    3.5 (1.6--7.5)   0.002   2.1 (0.6--7.7)   0.24
  Chromosomal aberration          3.7 (1.--7.1)                              \<0.001                                 3.8 (1.5--9.8)   0.006   2.3 (1.1--4.7)   0.021   4.1 (1.6--11)    0.004
  Age at diagnosis \>48 months    1.0 (0.5--1.8)                             0.94                                    2.2 (0.9--5.2)   0.09    0.7 (0.4--1.4)   0.35    1.8 (0.7--4.5)   0.2
  HbF \>15%                       1.7 (0.8--3.7)                             0.15                                    1.9 (0.5--7.4)   0.33    1.0 (0.4--2.2)   0.92    1.2 (0.3--5.2)   0.79
  PLT \<33 × 10^9^/L              2.0 (1.1--3.5)                             0.02                                    2.8 (1.2--6.2)   0.015   1.6 (0.9--3.0)   0.1     3.1 (1.4--7.3)   0.007
  Aberrant methylation score ≥1   --                                         --                                      --               --      4.1 (1.5--11)    0.006   4.4 (1.7--11)    0.002

Abbreviations: CI, confidence interval; HbF, hemoglobin F; HR, hazard ratio; PLT, platelets.

Discussion {#sec007}
==========

Negative regulation by aberrant methylation of the CpG islands of tumor-suppressor genes accounts for the pathogenesis of malignancy \[[@pone.0145394.ref011],[@pone.0145394.ref012]\]. In this study, we analyzed JMML cells from 92 children to measure the CpG methylation of 16 candidate genes by bisulfite conversion and pyrosequencing techniques. Aberrant methylation of six genes (*BMP4*, *CALCA*, *CDKN2A*, *CDKN2B*, *H19*, and *RARB*) was detected in 4%--45% of our cohort. Four of these genes (*BMP4*, *CALCA*, *CDKN2B*, and *RARB*) were consistent with those identified in the EWOG-MDS report, which described that CpG hypermethylation of these four genes was significantly associated with poor prognosis in JMML. Of note, the method for measuring methylation in the current study was different from that used in the EWOG-MDS study \[[@pone.0145394.ref017]\], suggesting that both methods can analyze targeted CpG methylation, supporting the reasonability of both studies.

In our study, aberrant methylation of four genes (*BMP4*, *CALCA*, *CDKN2A*, and *RARB*) was associated with poor prognosis. In contrast, EWOG-MDS study incorporated *CDKN2B* in the methylated gene sets, while *CDKN2A* was not included. In the current study, patients with an aberrant methylation of *CDKN2B* tended to show a poorer outcome (p = 0.11); however, in the current cohort, the size of the population with aberrant *CDKN2B* was small (4 of 92) compared with the population size (28 of 127) observed in the EWOG study. This difference may reflect the use of different methodologies in the two studies (pyrosequencing in the present study and MassARRAY in the EWOG study). *CDKN2A*, also known as *p16*, is coded in 9p21, and binds to *CDK4*, inhibiting the ability of *CDK4* to interact with cyclin D and stimulate passage through the G1 phase of the cell cycle \[[@pone.0145394.ref028]\]. The role of *CDKN2A* in leukemogenesis is well investigated. The first report in 1994 demonstrated that both alleles of *p16* were completely or partially deleted in human leukemia cells derived from patients \[[@pone.0145394.ref029]\]. Hemizygous deletions and rearrangements of 9p21 are reported as among the most frequent cytogenetic abnormalities detected in pediatric acute lymphoblastic leukemia \[[@pone.0145394.ref030]\]. A genome-wide analysis demonstrated that a common variation at 9p21.3 (intron 1 of *CDKN2A*) influences the risk of childhood acute lymphoblastic leukemia \[[@pone.0145394.ref031]\].

The current study indicated that aberrant methylation of multiple genes is a common phenomenon in JMML; specifically, 73% of patients exhibited methylation of at least one of four genes (*BMP4*, *CALCA*, *CDKN2A*, and *RARB*), whereas 40% of all patients had two or more genes methylated. These observations suggest that the patient cohort of JMML includes a CpG island methylator phenotype \[[@pone.0145394.ref017],[@pone.0145394.ref032]\]. Moreover, methylation of multiple genes was significantly associated with mutations in *SETBP1* or *JAK3*, which were involved in the progression rather than initiation of JMML \[[@pone.0145394.ref007]\]. Both aberrant methylation and secondary genetic mutations are associated with poor clinical outcomes, reflecting the aggressive disease at diagnosis of JMML. Indeed, our analyses identified that aberrant methylation is one of the independent poor prognosis factors for outcomes and refined the predictability of outcomes. The prognosis of patients with hypermethylation in three or all four genes was not improved by HSCT, as the most frequent cause of death in these patients was progression of JMML despite HSCT.

The most exciting finding in the current study was that patients with JMML could be classified using the AMS. The AMS 0 cohort exhibited significantly better TFS than the AMS 1--2 and 3--4 cohorts. At the same time, the AMS 0 and 1--2 cohorts displayed significantly better OS than the AMS 3--4 cohort. These results suggest that allogeneic HSCT improves the survival of patients with an AMS of 1--2 but not 3--4, providing new insight into clinical decision-making for patients with JMML. First, patients without aberrant methylation may survive without allogeneic HSCT, indicating that for careful observation, a more specific prognostic marker may need to be identified. Second, for patients with an AMS of 1--2, we provided evidence that early HSCT may improve their outcomes. Finally, for patients with an AMS of 3--4 for whom HSCT does not improve the prognosis, alternative therapies, including DNA methyltransferase inhibitors and new molecular-targeting agents, should be established as treatment options.

Epigenetic analysis provides helpful information for clinicians to select treatment strategies for patients with JMML. Our findings unmasked a new aspect of the molecular pathogenesis of JMML, which could facilitate the development of novel therapies; however, the study had some limitations. We assessed methylation using materials obtained only at diagnosis but not at later time points. In addition, our assessments were done for only 16 selected genes, whereas genome-wide profiling was not performed. Moreover, our analyses were possibly influenced by race bias. As JMML is an extremely rare disease, an international prospective study with risk classification by genetic and epigenetic analysis is warranted.

Supporting Information {#sec008}
======================

###### Kaplan--Meier curves for transplantation-free and overall survival stratified by risk groups based on a multivariate survival model.

Patients were divided into three groups based on a multivariate analysis model lacking the aberrant methylation score (AMS), i.e., the presence of a PTPN11 or NF1 mutation, chromosomal aberration, and low platelet count (\<33 × 109/L). We defined patients as having low (Low; without any covariates), intermediate (Int; with 1 covariate), and high risk (High; with ≥2 covariates). When we incorporated AMS in the patient stratification, patients were divided into three groups based on a multivariate analysis model including AMS (AMS model), i.e., the presence of a PTPN11 or NF1 mutation, chromosomal aberration, low platelet count (\<33 × 109/L), and high AMS (AMS ≥1 for TFS). We defined patients as having low (Low-M; without any covariates), intermediate (Int-M; with 1 covariates), and high risk (High-M; with ≥3 covariates) using the AMS model. Kaplan--Meier curves represent the probabilities of TFS based on the two models (panels A, B).

(TIFF)

###### 

Click here for additional data file.

###### Summary of targeted CpGs in candidate genes.

Primers for targeted CpGs in each gene, excluding RARB, were supplied by commercial companies. Thus, the primers for APC (product code \#ASY516), BMP4 (\#ADS1490), CALCA (\#ADS1489), CDH13 (\#ADS1461), CDKN2B (\#ADS708), CHFR (\#ADS1462), DAPK1 (\#ADS040), ESR1 (\#ADS076), H19 (\#ADS596), IGF2 (\#ADS1051), and RASSF1 (\#ASY574) were supplied by EPIGENDX (Hopkinton, MA, USA), while those for TP73 (\#ADS658), CDKN2A (\#972012), MGMT (\#972032), and MLH1 (\#972022) were supplied by QIAGEN. PCR primers and the sequencing primer for the CpGs of RARB were as reported by Shaw et al. The sequence informations of targeted CpGs in candidate genes were summarized as bellow.

(PDF)

###### 

Click here for additional data file.
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